TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)—Exploration of germline DDR alteration landscape and ...
Recent studies have highlighted the CD2-CD58 axis's relevance in cancer immunotherapy, suggesting its potential to enhance anti-tumor immunity and making it a promising target for therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results